CN104161769A - Cyclic adenosine monophosphate-containing composition and applications thereof - Google Patents

Cyclic adenosine monophosphate-containing composition and applications thereof Download PDF

Info

Publication number
CN104161769A
CN104161769A CN201410404023.9A CN201410404023A CN104161769A CN 104161769 A CN104161769 A CN 104161769A CN 201410404023 A CN201410404023 A CN 201410404023A CN 104161769 A CN104161769 A CN 104161769A
Authority
CN
China
Prior art keywords
adenosine cyclophosphate
parts
diphenhydramine
compositions
adenosine monophosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410404023.9A
Other languages
Chinese (zh)
Other versions
CN104161769B (en
Inventor
李捍雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euphorbia Biological Medicine Co ltd
Guangdong Zerui Pharmaceutical Co ltd
Guangzhou Lianrui Pharmaceutical Co ltd
Guangzhou Runlin Pharmaceutical Technology Co ltd
GUANGZHOU YIPINHONG PHARMACEUTICAL CO Ltd
Original Assignee
GUANGZHOU YIPINHONG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGZHOU YIPINHONG PHARMACEUTICAL CO Ltd filed Critical GUANGZHOU YIPINHONG PHARMACEUTICAL CO Ltd
Priority to CN201410404023.9A priority Critical patent/CN104161769B/en
Publication of CN104161769A publication Critical patent/CN104161769A/en
Application granted granted Critical
Publication of CN104161769B publication Critical patent/CN104161769B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a cyclic adenosine monophosphate-containing composition and applications thereof. According to the formula, the composition is prepared from the following components in parts by weight: 10-12 parts of cyclic adenosine monophosphate, 6-9 parts of diphenhydramine, 5-8 parts of vinpocetine and 2-3 parts of nicotinic acid. The cyclic adenosine monophosphate-containing composition has a good treatment effect on myocardial infarction by virtue of the combination of cyclic adenosine monophosphate, diphenhydramine, vinpocetine and nicotinic acid.

Description

A kind of compositions and application thereof containing adenosine cyclophosphate
Technical field
The present invention relates to new drug development technical field, relate in particular to the exploitation for the treatment of of myocardial infarction medicine, be specifically related to a kind of compositions and application thereof containing adenosine cyclophosphate.
Background technology
Myocardial infarction is that coronary artery is acute, the caused impatient necrosis of persistence Hypoxia and ischemia.Because of modern live custom change, the appearance of the problems such as the quickening of rhythm of life, the sickness rate of China recent years myocardial infarction is obvious ascendant trend, annual new at least 50 ten thousand, now suffer from least 200 ten thousand, therefore, be devoted to research and develop new effective treatment of myocardial infarction medicine, tool has very important significance and wide market prospect.
Adenosine cyclophosphate, chemical name is 6-amino-9-β-D-RIBOSE base-9H-purine-4`, 5`-cycli phosphate hydrogen ester, molecular formula is C 10h 12n 5o 6p is white or off-white powder; Adenosine cyclophosphate is as the second message,second messenger's material that participates in regulating cell function, and its effect is very extensive, injects heavy dose of adenosine cyclophosphate, can make myocardial contraction strengthen, and causes elevation of the blood pressure, and cardiac output increases.And can diastole smooth muscle, coronary artery dilator blood vessel, improve liver function, suppress the division of skin outer layer epithelial cell and transform paracytic function, promote the oxidasic activity of respiratory chain and improve myocardial ischemia etc.
Diphenhydramine, molecular formula is C 17h 21nOHCl is white crystalline powder; Diphenhydramine is antihistaminic, has the effect of antihistaminic H1 receptor, and nervus centralis is had to stronger inhibitory action.
Vinpocetine, molecular formula is C 22h 26n 2o 2, be white loose block or powder, be usually used in improving the various symptoms that cerebral infarction sequela, apoplexy sequela, cerebral arteriosclerosis etc. are brought out.
Nicotinic acid, also referred to as vitamin B 3, molecular formula is C 6h 5nO 2, colourless acicular crystal, has stronger expansion peripheral vessels effect, clinical headache, migraine, tinnitus, the auditory vertigo etc. of being used for the treatment of.
At present, there is not yet the correlational study for treatment of myocardial infarction by diphenhydramine, vinpocetine, also do not have the correlational study report that diphenhydramine, vinpocetine and nicotinic acid collocation adenosine cyclophosphate is used for the treatment of to myocardial infarction.
Summary of the invention
The object of this invention is to provide a kind of compositions myocardial infarction, that contain adenosine cyclophosphate that is used for the treatment of.
Another object of the present invention is to provide the application of above-mentioned composition in preparation treatment myocardial infarction medicine.
Above-mentioned purpose of the present invention is achieved by following scheme:
Containing a compositions for adenosine cyclophosphate, the formula of said composition is made up of the each component of following parts by weight:
The preferred version of combinations thereof composition formula is as follows:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and crossed after 100 mesh sieves, according to formula consumption, mix, then put into dry 30 minutes of the baking oven of 55-60 DEG C, prepare the compositions containing adenosine cyclophosphate of the present invention.
The above-mentioned compositions containing adenosine cyclophosphate can be made various dosage forms with pharmaceutically acceptable carrier or excipient, as tablet, granule, capsule or injection etc.
Compositions containing adenosine cyclophosphate of the present invention, through experimentation, has good treatment myocardial infarction effect, therefore, can be used for the medicine of preparation treatment myocardial infarction.
Compared with prior art, the present invention has following beneficial effect:
1. the compositions containing adenosine cyclophosphate of the present invention, introduces diphenhydramine, vinpocetine in the research for the treatment of myocardial infarction medicine first, by by adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid compatibility, has played the effect for the treatment of well myocardial infarction;
2. the compositions containing adenosine cyclophosphate of the present invention, in its formula, each composition is all that basic research and clinical practice confirm there is no obvious toxic-side effects, and between each composition, there is no the taboo of compatibility, without ill effect mutually, therefore has safety.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is done further and described, but specific embodiment does not do any restriction to the present invention.
Embodiment 1
Compositions containing adenosine cyclophosphate of the present invention, the formula of said composition is made up of the each component of following parts by weight:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and crossed after 100 mesh sieves, according to formula consumption, mix, then put into dry 30 minutes of the baking oven of 55-60 DEG C, prepare the compositions containing adenosine cyclophosphate of the present embodiment.
Embodiment 2
Compositions containing adenosine cyclophosphate of the present invention, the formula of said composition is made up of the each component of following parts by weight:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and crossed after 100 mesh sieves, according to formula consumption, mix, then put into dry 30 minutes of the baking oven of 55-60 DEG C, prepare the compositions containing adenosine cyclophosphate of the present embodiment.
Embodiment 3
Compositions containing adenosine cyclophosphate of the present invention, the formula of said composition is made up of the each component of following parts by weight:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and crossed after 100 mesh sieves, according to formula consumption, mix, then put into dry 30 minutes of the baking oven of 55-60 DEG C, prepare the compositions containing adenosine cyclophosphate of the present embodiment.
Comparative example 1
The compositions of this comparative example, its formula is made up of the each component of following parts by weight:
8 parts of diphenhydramine;
6 parts of vinpocetines;
2 parts, nicotinic acid.
The preparation method of above-mentioned composition is as follows:
Diphenhydramine, vinpocetine and nicotinic acid are ground respectively and crossed after 100 mesh sieves, according to formula consumption, mix, then put into dry 30 minutes of the baking oven of 55-60 DEG C, prepare the compositions of this comparative example.
Embodiment 4 myocardial infarction model experiments
Taking mice as experimental subject, every group of 10 mices, establish 6 groups altogether, specific as follows shown in:
(1) blank group: experimental drug is water for injection.
(2) experimental group 1: experimental drug is a kind of compositions containing adenosine cyclophosphate prepared by embodiment 1;
(3) experimental group 2: experimental drug is a kind of compositions containing adenosine cyclophosphate prepared by embodiment 2;
(4) experimental group 3: experimental drug is a kind of compositions containing adenosine cyclophosphate prepared by embodiment 3;
(5) matched group 1: experimental drug is compositions prepared by comparative example 1;
(6) matched group 2: experimental drug is adenosine cyclophosphate.
Experimental model is myocardial infarction model, causes after each group of experiment mice myocardial necrosis intravenously administrable with isoproterenol, every day twice, the dosage of each experimental drug is 5mg/kg, and administration is after 20 days, observe mice survival rate (%), result is as follows:
(1) blank group: survival rate 0;
(2) experimental group 1: survival rate 90%;
(3) experimental group 2: survival rate 90%;
(4) experimental group 3: survival rate 100%;
(5) matched group 1: survival rate 20%;
(6) matched group 2: survival rate 70%.
Can find out from above-mentioned experimental result, compare with simple use adenosine cyclophosphate or use diphenhydramine, vinpocetine and nicotinic acid combination, the compositions containing adenosine cyclophosphate of the present invention has the effect of good treatment myocardial infarction.

Claims (4)

1. containing a compositions for adenosine cyclophosphate, it is characterized in that the formula of said composition is made up of the each component of following parts by weight:
Adenosine cyclophosphate 10-12 part;
Diphenhydramine 6-9 part;
Vinpocetine 5-8 part;
Nicotinic acid 2-3 part.
2. according to claim 1 containing the compositions of adenosine cyclophosphate, it is characterized in that the formula of described compositions is made up of the each component of following parts by weight:
11 parts of adenosine cyclophosphate;
8 parts of diphenhydramine;
6 parts of vinpocetines;
2 parts, nicotinic acid.
3. according to the compositions containing adenosine cyclophosphate of any one described in claim 1 or 2, it is characterized in that the described compositions containing adenosine cyclophosphate is tablet, granule, capsule or injection.
4. described in claim 1 or 2, contain the compositions of adenosine cyclophosphate in the application of preparing in the medicine for the treatment of myocardial infarction.
CN201410404023.9A 2014-08-16 2014-08-16 A kind of compositions containing adenosine cyclophosphate and application thereof Active CN104161769B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410404023.9A CN104161769B (en) 2014-08-16 2014-08-16 A kind of compositions containing adenosine cyclophosphate and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410404023.9A CN104161769B (en) 2014-08-16 2014-08-16 A kind of compositions containing adenosine cyclophosphate and application thereof

Publications (2)

Publication Number Publication Date
CN104161769A true CN104161769A (en) 2014-11-26
CN104161769B CN104161769B (en) 2016-01-20

Family

ID=51905895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410404023.9A Active CN104161769B (en) 2014-08-16 2014-08-16 A kind of compositions containing adenosine cyclophosphate and application thereof

Country Status (1)

Country Link
CN (1) CN104161769B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562346A (en) * 2004-04-05 2005-01-12 杨喜鸿 Compound preparation of cyclicamp or its ramification and counteractant for free radical
CN101791310A (en) * 2010-02-24 2010-08-04 王保明 Vinpocetine medicine composition and preparation method thereof
CN102802618A (en) * 2009-06-25 2012-11-28 泰特拉有限公司 Therapeutic Combinations Of Nicotinic Acid And Meldonium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562346A (en) * 2004-04-05 2005-01-12 杨喜鸿 Compound preparation of cyclicamp or its ramification and counteractant for free radical
CN102802618A (en) * 2009-06-25 2012-11-28 泰特拉有限公司 Therapeutic Combinations Of Nicotinic Acid And Meldonium
CN101791310A (en) * 2010-02-24 2010-08-04 王保明 Vinpocetine medicine composition and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李兴、段立广: "HPLG法测定冠心膏中盐酸苯海拉明的含量", 《中国实用医药》, vol. 7, no. 12, 30 April 2012 (2012-04-30), pages 260 - 261 *

Also Published As

Publication number Publication date
CN104161769B (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US20170266213A1 (en) Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products
US20210179632A1 (en) Thienopiperidine derivative and use thereof
US20170080011A1 (en) Use of nadh and nmn in preparation of drugs or health-care products for treating parkinson's disease
CN108721281A (en) New antiviral drugs and its application
CN106822905A (en) The medicine and purposes of inhibitor containing Survivin and IRE1 inhibitor
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
CN101220071B (en) Stable 6-methoxy-2',3'-dideoxy guanine nucleoside, method for preparing the same and medicament composition containing the same
CN104161769B (en) A kind of compositions containing adenosine cyclophosphate and application thereof
CN103919765B (en) Dinatin application in preparation catechol medicament synergistic agent and comprise the pharmaceutical composition of dinatin
CN106309441A (en) Application of Fistulains A in preparation of drugs for treating cervical cancer
CN105726558A (en) Composition containing meglumine adenosine cyclophosphate and application thereof
CN103520170B (en) Kadcoccitones A application in preparation treatment myocardial ischemia drug
CN102872059B (en) Application of Gypensapogenin B to preparing drugs for resisting human funguses
CN107115340B (en) Antituberculosis drug, preparation method and application thereof
CN105456272A (en) Application of Biscarpamontamine A in preparing medicine for increasing red blood cells
CN106176737A (en) A kind of have synergistic active component and Febustat compositions thereof with antihyperuricemic disease drug
CN102988351A (en) Application of Aphanamixoid A for preparing medicine for treating myocardial ischemia
CN103462989A (en) Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi
CN102861027B (en) Application of Gypensapogenin A in medicine for preventing human fungi
CN102872133B (en) Application of Houttuynoid E in anti-human fungal drugs
CN103356681B (en) The application of Houttuynoid A in preparation treatment myocardial ischemia drug
CN102872007A (en) Application of Eryngiolide A in medicaments resisting human body fungi
CN105535054A (en) Compound powder for preventing and treating coccidiosis in chickens and preparation method of compound powder
CN106344578A (en) Application of Fistulains A in anti-hypoxic drugs
CN106309426A (en) Application of Fistulains B in human fungus resisting drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20221111

Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000

Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd.

Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd.

Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd.

Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd.

Patentee after: Euphorbia Biological Medicine Co.,Ltd.

Address before: Building 1, No. 6, Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangzhou, Guangdong 510765

Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right